Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPXGet Free Report) was the target of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 56,700 shares, a decrease of 28.8% from the May 15th total of 79,600 shares. Based on an average trading volume of 98,600 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.8% of the company’s stock are sold short.

Virpax Pharmaceuticals Stock Performance

Virpax Pharmaceuticals stock opened at $0.69 on Friday. Virpax Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $11.77. The firm’s fifty day simple moving average is $1.96 and its 200-day simple moving average is $3.01.

Virpax Pharmaceuticals (NASDAQ:VRPXGet Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($2.75) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, May 22nd.

Get Our Latest Stock Analysis on VRPX

About Virpax Pharmaceuticals

(Get Free Report)

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Recommended Stories

Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with's FREE daily email newsletter.